Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
High-dose intravenous corticosteroids are effective in treating acute optic neuritis.1
However, certain ophthalmological conditions should be considered before treatment as they can be worsened by corticosteroids: this emphasises the need for collaboration between neurologists and neuro-ophthalmologists.2 ,3
A 47-year-old man presented in 1999 with right-sided optic neuritis. This was treated with intravenous corticosteroids and he made a good recovery, with post-treatment visual acuity of 6/6. Between 1999 and 2004, he had several episodes of sensory symptoms, not requiring treatment. Imaging corroborated the clinical diagnosis of multiple sclerosis4 and he was treated with weekly interferon ß1a (Avonex) 30 µg. In 2005, he presented with a left optic neuritis, treated by high dose corticosteroids and again with good ophthalmological recovery. Unfortunately, in 2006, he began to develop a progressive paraplegia. He then presented with bilateral impairment of vision, with decreased visual acuity to 6/19 (right) and 6/9.5 (left). He did not undergo dilated fundus examination. He also reported worsening of the motor symptoms and sphincter disturbance. Intravenous high-dose corticosteroids treatment was started and, despite the treatment, he reported a painless decrease of visual acuity in the right eye, with a scotoma resembling a …
Contributors MS, individual contribution to the manuscript—Drafting, revising, conducting and reporting the manuscript's content, including medical writing of content. AD, individual contribution to the manuscript—Drafting, revising and planning the manuscript's content, including medical writing of content. BP, individual contribution to the manuscript—Drafting and reporting the manuscript's content. SAF, individual contribution to the manuscript—Revising the manuscript's content, including medical writing of content. DB-G, individual contribution to the manuscript—Conducting and revising the manuscript's content, including medical writing of content. MS and AD, are responsible for the overall content as guarantors.
Competing interests None.
Provenance and peer review Not commissioned. Externally peer reviewed. This paper was reviewed by Mark Lawden, Leicester, UK.
Read the full text or download the PDF:
Other content recommended for you
- Photodynamic therapy for steroid-associated central serous chorioretinopathy
- Retinal and choroidal changes observed with ‘En face’ enhanced-depth imaging OCT in central serous chorioretinopathy
- Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy
- Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy
- Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study
- Spironolactone versus observation in the treatment of acute central serous chorioretinopathy
- Discrepancy in current central serous chorioretinopathy classification
- Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy
- Mimics and chameleons of optic neuritis
- Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level